A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT07676006 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Interventions

BIOLOGICAL: GT737 Injection

Sponsor

Grit Biotechnology

Collaborators

[object Object]